At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
MC2-01 Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Open-label, Maximal Use Trial, Evaluating the Pharmacokinetic Profile of Active Ingredients and Their Metabolites After Application of MC2-01 Cream Compared With Active Comparator in Subjects With Extensive Psoriasis Vulgaris
In Brief
A Phase 2 clinical trial evaluating MC2-01 Cream and CAL/BDP combination for Psoriasis Vulgaris. Completed, enrolled 63 participants across 1 site.
Detailed Summary
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedMar 2018
Primary CompletionAug 2018
TodayJul 2026
First PostedMar 13, 2018
Enrollment StartFeb 8, 2018
Primary CompletionAug 4, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.3 years ago
Interventions
MC2-01 Creamdrug
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
CAL/BDP combinationdrug
Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)